|Bid||32.18 x 1800|
|Ask||32.49 x 1000|
|Day's Range||32.15 - 33.08|
|52 Week Range||31.54 - 47.82|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||37.15|
|Earnings Date||Nov 5, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||44.94|
HERTFORDSHIRE, England and PITTSBURGH, Oct. 19, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced that it has initiated the commercial launch of Hulio™, a biosimilar to AbbVie's Humira® (adalimumab), across major markets in Europe. Mylan President Rajiv Malik commented: "We're proud of our strategic partnership with Fujifilm Kyowa Kirin Biologics and the strong collaboration of our science and technology teams to bring Hulio to market for patients. As the cost of healthcare continues to rise around the world, we know the important role that biosimilars play to ensure patients can access the medicines they need.
HERTFORDSHIRE, England, PITTSBURGH and BENGALURU, India, Oct. 19, 2018 /PRNewswire/ -- Mylan N.V. (MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri®, a biosimilar to Roche's Herceptin® (trastuzumab). The CHMP positive opinion will now be considered by the European Commission.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 18) Endocyte, Inc. (NASDAQ: ECYT )( announced a deal to ...
HERTFORDSHIRE, England and PITTSBURGH, Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (MYL) today announced the U.S. launch of Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL Single-Dose Vial, a generic version of the brand drug, Pfizer's Depo-Provera®. Mylan is offering Medroxyprogesterone Acetate Injectable Suspension USP, 150 mg/mL Single-Dose Vial to its institutional customers after an Abbreviated New Drug Application (ANDA) for the product was approved by the U.S. Food and Drug Administration (FDA).
Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.
HERTFORDSHIRE, England and PITTSBURGH , Oct. 18, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2018 financial results, ...
When anger over EpiPen pricing erupted in 2016, generic drugmaker Mylan NV (NASDAQ: MYL ) was villainized. The price of the autoinjector used for severe allergic reactions was hiked by about 500 percent ...
Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included an old-school conglomerate and a social media pair. Bearish calls included an electric car maker ...
On Tuesday, the patent that for 15 years has protected Humira, the world’s best-selling prescription drug, from generic competition expires in Europe — triggering a tussle among a string of the most prominent names in the pharmaceuticals industry to secure a slice of a near $20bn global market. The development will turn a spotlight on the developing threat posed by the rise of biosimilars — and open up a new frontier in the industry’s attempt to secure an adequate return on its investment, as cash-strapped payers seize on this new wave of copycat drugs as a way to cut costs.
Court Affirms Prior Decisions Finding Copaxone® 40 mg/mL Patents Invalid HERTFORDSHIRE, England and PITTSBURGH , Oct. 12, 2018 /PRNewswire/ -- Mylan N.V . (NASDAQ: MYL) today announced that the United ...
A U.S. appeals court on Friday upheld a ruling that canceled patents owned by Teva Pharmaceutical Industries Ltd on its blockbuster multiple sclerosis drug Copaxone. The ruling was a victory for a group of generic drug companies, including Mylan NV and Novartis AG unit Sandoz, that challenged the validity of Teva's patents in order to sell generic versions. Teva did not immediately respond to requests for comment.
AbbVie (ABBV) strikes a deal with Sandoz, the generic arm of Novartis, to launch its biosimilar Humira in the United States on Sep 30, 2023.
On October 11, Teva Pharmaceutical Industries (TEVA) was trading at a forward PE (price-to-earnings) ratio of 7.5x compared to the industry average PE of 11.5x. Its forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple, a capital-structure-neutral valuation measure, is 10.4x, which is higher than the industry average of 9.4x. A company’s forward PE ratio reflects the market’s views in regards to the company’s growth potential over the next 12 months.
Teva Pharmaceutical Industries (TEVA) is gradually recovering from the lows it witnessed in late 2017 due to generics competition, pricing pressure, and declining Copaxone sales. Teva’s growth prospects have been boosted by the FDA’s recent approval of its migraine drug. In recent months, analysts have been more confident about the company’s growth prospects. As of October 11, 24 analysts covered Teva stock and were included in a recent Reuters survey.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 11, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that positive new data from multiple studies of YUPELRI™ (revefenacin) inhalation solution were presented at the 2018 CHEST annual meeting, which was held in San Antonio, Texas on October 6-10, 2018. The Prescription Drug User Fee Act (PDUFA) date for YUPELRI is November 13, 2018. If approved, YUPELRI would be the first and only once-daily, long-acting nebulized bronchodilator for the treatment of COPD. YUPELRI is designed to be compatible with any standard jet nebulizer.
Today, Morgan Stanley downgraded Mylan (MYL) from “overweight” to “equal weight.” The firm also cut its target price for MYL stock from $46 to $36. Also, Mylan has seen lower-than-expected sales from its biosimilar and complex products portfolio, which it’s increasingly focusing on in the wake of increasing generics competition and pricing pressures. Today, MYL stock fell ~2.7% during premarket trading.
Shares of Mylan N.V. dropped 1.4% toward a one-year low in afternoon trade Tuesday, after the drug maker was downgraded at Morgan Stanley on concerns over generic sales trends, risks to EpiPen from generic competition and biosimilars strategy that's less compelling that expected. Analyst David Risinger cut his rating to equal weight, saying his thesis for upgrading the stock to overweight in March is now "broken." He lowered his stock price target to $36, which is 3.1% above current levels, from $42. Back in March 2018 when we upgraded [Mylan] from EW to OW, we expected solid growth prospects versus peers, differentiated pipeline progress and positive catalysts," Risinger wrote in a note to clients. "But newsflow has disappointed, and we fear further pressure even though we still expect Mylan to receive FDA approval of its generic Advair imminently." The stock has shed 17.7% year to date, while the SPDR Health Care Select Sector ETF has rallied 14.5% and the S&P 500 has gained 8.0%.
Even with positive near-term catalysts, Mylan NV (NASDAQ: MYL ) suffers from “uncertain prospects” that warrant a neutral stance, according to Morgan Stanley. The Rating Analyst David Risinger downgraded ...
Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company will present two-year clinical data from its Phase II study of GA Depot for the treatment of relapsing remitting multiple sclerosis (RRMS) at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), which will take place on October 10-12 in Berlin, Germany. The results will be featured as part of Poster Session #3, on Friday, October 12th, 2018, between 12:15pm and 2:15pm CET and as an e-poster.
DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Oct. 8, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (TBPH) ("Theravance Biopharma") and Mylan N.V. (MYL) ("Mylan") today announced that data from studies of YUPELRI™ (revefenacin) will be presented at the 2018 CHEST annual meeting, being held in San Antonio, Texas on October 6-10, 2018. Researchers will also report data from a new study comparing outcomes for YUPELRI and tiotropium (Spiriva® HandiHaler®) in COPD patients with suboptimal peak inspiratory flow rates (PIFR). YUPELRI is an investigational long-acting muscarinic antagonist (LAMA) currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of COPD.
GW Pharmaceuticals (GWPH) is a leader in the development of plant-derived cannabinoid therapeutics. GW Pharmaceuticals reported EPS of -$1.26 on revenues of $3.46 million in the third quarter. It was a 10.2% revenue growth year-over-year.